低级别非肌层浸润性膀胱癌的长期复发风险、转移潜能与膀胱镜监测时长
该回顾性研究纳入1989至2019年一所学术中心的521例原发性Ta低级别非肌层浸润性膀胱癌或低恶性潜能乳头状尿路上皮肿瘤患者,中位随访9.6年,分析复发、进展、转移与膀胱癌死亡风险,并用RNAseq评估4例转移灶的转录组谱,另由3位专家病理医生盲法评估80例病理分级一致性。
要点
- 521例中350例复发、57例进展、20例转移、15例死于膀胱癌,5/10/15年癌特异生存概率分别为0.99、0.98、0.96。
- 前5年无复发者中50例出现晚期复发、其中2例死于膀胱癌。
- WHO 2004/2022分级一致性为0.78(95%CI 0.65-0.90),WHO 1973为0.41(95%CI 0.32-0.50)。
核心结论
- 长期数据显示原发性Ta低级别非肌层浸润性膀胱癌并非几乎从不进展为致死性疾病,但前5年无复发者膀胱癌相关死亡风险极低。
- 病理分级变异性的最小化仍是未满足的需求。
研究设计与样本
- 回顾性研究,纳入1989至2019年一所学术中心诊断的原发性Ta低级别非肌层浸润性膀胱癌491例与低恶性潜能乳头状尿路上皮肿瘤30例,共521例。
- 数据来自病历回顾与该中心膀胱癌信息登记库,分析复发、分期进展至肌层浸润、转移及膀胱癌死亡风险。
- 对4例发生转移的Ta低级别非肌层浸润性膀胱癌行RNAseq转录组分析;由3位专家病理医生盲法评估80例的病理分级观察者间变异(WHO 2004/2022与1973)。
主要发现
- 中位随访9.6年(95%CI 8.6-10.2),521例中73%为男性、中位年龄67.0岁;350例复发、57例分期进展、20例发生转移、15例死于膀胱癌(诊断后中位9.6年)。
- 5、10、15年癌特异生存概率分别为0.99、0.98、0.96。
- 前5年无复发的患者中50例发生晚期复发,其中2例死于膀胱癌。
- 发生转移的Ta低级别非肌层浸润性膀胱癌在表型上与惰性肿瘤相似,但转录组呈现与更高级别肿瘤一致的不良发现。
- WHO 2004/2022分级一致性为0.78(95%CI 0.65-0.90),WHO 1973分级一致性为0.41(95%CI 0.32-0.50)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with Ta low-grade (LG) nonmuscle-invasive bladder cancer (NMIBC) rarely develop metastases or die of it. Long-term data are scant and length of follow-up poorly defined. MATERIALS AND METHODS: This retrospective study included 521 patients diagnosed with primary TaLG NMIBC (n = 491) or papillary urothelial neoplasm of low malignant potential (n = 30) from 1989 to 2019 at an academic center. Patient data were acquired using patient records chart review and a bladder cancer informatics registry at the center. Risk of recurrence and progression in stage to muscle invasion, metastases, and death due to bladder cancer (BC) were analyzed. RNAseq assessed the transcriptomic profiles of 4 TaLG NMIBCs that metastasized. Interobserver variability in pathological grading (WHO 2004/2022 and 1973, n = 80) was blindly assessed by 3 expert pathologists. RESULTS: The median follow-up was 9.6 (95% CI: 8.6-10.2) years. Among 521 patients (73% men, median age 67.0 years), 350 recurred, 57 progressed in stage, 20 developed metastases, and 15 died of BC (median 9.6 years after diagnosis). Cancer-specific survival probabilities were 0.99, 0.98, and 0.96 at 5, 10, and 15 years, respectively. Fifty patients who were recurrence free for the first 5 years developed late recurrences and 2 of them died of BC. Metastatic TaLG NMIBC had more adverse transcriptomic findings in keeping with higher-grade tumors despite being phenotypically similar to indolent tumors. Grading concordance for the 2004/2022 system and WHO 1973 was 0.78 (95% CI: 0.65-0.90) and 0.41 (95% CI: 0.32-0.50), respectively. CONCLUSIONS: This study with long-term data challenges the assumption that primary TaLG NMIBC nearly never progresses to lethal disease if followed long enough. However, the risk of BC-related mortality is extremely low in patients who are recurrence free for the first 5 years. Minimizing variability in pathological grading remains an unmet need.
引用
- Villegas E, Lajkosz K, Din S, et al. Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder Cancer. J Urol. 2024. PMID: 39470318. doi:10.1097/JU.0000000000004305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。